Societal Debates About Emerging Genetic Technologies: Toward a Science of Public Engagement
By Christopher D. Wirz,
Environmental Communication
| 09. 29. 2020
Gene editing is an inherently wicked problem
Societal debates about the applications of novel gene editing techniques like CRISPR in agriculture, wildlife, and humans have only rarely focused on questions that have correct or even factual answers. Of course, many discussions within the bench scientific community are focused on technical risks and benefits and the weighing of the latter against the former in the desire to develop climate- or pest-resistant crops (National Academies of Sciences, 2016) or therapies for devastating genetically-inherited diseases in humans (National Academy of Sciences & National Academy of Medicine, 2017).
While public debates are ideally informed by these scientific considerations, they are – by nature – much broader in scope. Gene drives developed to limit the spread of vector-borne illness carried by mosquitos, for instance, have raised concerns about the morality of “messing with nature” by editing the genome of living organisms for dominant traits, about creating imbalances in already fragile ecosystems, and about unintended and potentially irreversible long-term consequences for humans and nature (Brossard et al., 2019). At the same time, pesticides...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...